DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450)

South Korea · Delayed Price · Currency is KRW

21,500

+1,400 (6.97%)

Aug 11, 2026, 12:00 PM KST

15.78% (1Y)

Market Cap	906.73B +10.0%
Revenue (ttm)	954.16B +13.7%
Net Income	74.52B +28.5%
EPS	1,659.97 +28.0%
Shares Out	45.11M
PE Ratio	12.11
Forward PE	9.52
Dividend	200.00 (1.04%)
Ex-Dividend Date	Dec 29, 2025

Volume	470,097
Open	20,200
Previous Close	20,100
Day's Range	20,050 - 22,200
52-Week Range	16,260 - 31,250
Beta	-0.03
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About DongKook Pharmaceutical

DongKook Pharmaceutical Co., Ltd. produces and sells pharmaceutical products in South Korea and internationally. The company offers non-prescription and prescription drugs, quasi drugs, medical devices, active pharmaceutical ingredients, cosmetics, and other products. Its pipeline includes DKF-MB601, used to treat Hepatitis B; DKF-MB501, to treat obesity; DKM-412 and DKM-420 to treat osteoarthritis; DKF-313, indicated for benign prostatic hyperplasia; DKF-447, to treat diabetes; DKB-123, used for wound healing, tissue repair; and DKM-428, used ... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1968

Employees 1,255

Stock Exchange KOSDAQ

Ticker Symbol 086450

Full Company Profile

Financial Performance

In 2025, DongKook Pharmaceutical's revenue was 926.88 billion, an increase of 14.12% compared to the previous year's 812.17 billion. Earnings were 66.02 billion, an increase of 8.64%.

Financial Statements